Company Performance - Aligos Therapeutics reported a quarterly loss of 1.91, representing an earnings surprise of -78.53% [1] - The company's revenues for the quarter ended December 2024 were 2.68 million a year ago [2] - Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Movement and Outlook - Aligos Therapeutics shares have declined approximately 67.5% since the beginning of the year, contrasting with the S&P 500's decline of -1.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is -1 million in revenues, and for the current fiscal year, it is -4 million in revenues [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Aligos Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aligos Therapeutics' stock performance [5][6]
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates